Case Report : Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19
Copyright © 2022 Leone, Imeraj, Gastoldi, Mele, Liguori, Condemi, Ruggenenti, Remuzzi and Carrara..
Hemolytic uremic syndrome (HUS) is a rare life-threatening disease of unrestrained complement system dysregulation, microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure in genetically predisposed individuals. In this report, we describe two cases of SARS-CoV-2-associated HUS treated with eculizumab, a C5-blocking monoclonal antibody reported to be remarkably effective in the treatment of HUS. Detailed biochemical and genetic complement system analysis is reported, and the prompt clinical response after C5 pharmacological blockade is documented. Our report provides the rationale and supports the use of terminal complement pathway inhibition for the treatment of SARS-CoV-2-associated HUS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in pharmacology - 13(2022) vom: 11., Seite 842473 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Leone, Valentina Fanny [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 19.03.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fphar.2022.842473 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338259783 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338259783 | ||
| 003 | DE-627 | ||
| 005 | 20231226000255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2022.842473 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1127.xml |
| 035 | |a (DE-627)NLM338259783 | ||
| 035 | |a (NLM)35295324 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Leone, Valentina Fanny |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Case Report |b Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.03.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022 Leone, Imeraj, Gastoldi, Mele, Liguori, Condemi, Ruggenenti, Remuzzi and Carrara. | ||
| 520 | |a Hemolytic uremic syndrome (HUS) is a rare life-threatening disease of unrestrained complement system dysregulation, microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure in genetically predisposed individuals. In this report, we describe two cases of SARS-CoV-2-associated HUS treated with eculizumab, a C5-blocking monoclonal antibody reported to be remarkably effective in the treatment of HUS. Detailed biochemical and genetic complement system analysis is reported, and the prompt clinical response after C5 pharmacological blockade is documented. Our report provides the rationale and supports the use of terminal complement pathway inhibition for the treatment of SARS-CoV-2-associated HUS | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a coronavirus disease 2019 (COVID-19) | |
| 650 | 4 | |a eculizumab | |
| 650 | 4 | |a hemolytic uremic syndrome | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2) | |
| 650 | 4 | |a thrombotic microangiopathy | |
| 700 | 1 | |a Imeraj, Amantia |e verfasserin |4 aut | |
| 700 | 1 | |a Gastoldi, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Mele, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Liguori, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Condemi, Carmelita |e verfasserin |4 aut | |
| 700 | 1 | |a Ruggenenti, Piero |e verfasserin |4 aut | |
| 700 | 1 | |a Remuzzi, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Carrara, Camillo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in pharmacology |d 2010 |g 13(2022) vom: 11., Seite 842473 |w (DE-627)NLM208568891 |x 1663-9812 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g day:11 |g pages:842473 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fphar.2022.842473 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |b 11 |h 842473 | ||